Rineterkib
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF[1][2].
Product Specifications
CAS Number
[1715025-32-3]
UNSPSC
12171500
Target
ERK; Raf
Type
Dye Reagents
Related Pathways
MAPK/ERK Pathway; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ERK-IN-1.html
Purity
99.70
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](C1=CC(F)=CC(Br)=C1)CNC)C2=CC=C(C3=NC([C@@H]4C[C@H](F)[C@@H](O)CC4)=CN=C3N)C=C2F
Molecular Formula
C26H27BrF3N5O2
Molecular Weight
578.42
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Dye Reagents
Clinical Information
Phase 2
Isoform
ERK1; ERK2; Raf
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Rabbit IgG (Fc specific, Heavy Chain) (1E1) Mouse Mouse Monoclonal Antibody
PRPSAP2 CRISPR All-in-one AAV vector set (with saCas9)(Human)
